ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Increasing evidences suggest that inducing oncoprotein degradation is a novel and effective therapeutic approach [9,10], and small compounds are promising candidates for reducing BCR-ABL expression and have been regarded as potential drug candidates for CML treatment.